Cytokinetics | CYTK - Net Income

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
74.33

Cytokinetics reported $-206.03M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Arca Biopharma USD -29.58M 694K Dec/2025
Bayer EUR 2.76B 6.52B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Brainstorm Cell Therapeutics USD -2.11M 797K Sep/2025
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Exelixis USD 210.47M 34.06M Mar/2026
Geron USD -3.64M 27.5M Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026